Preclinical study demonstrates that LncRNA BACE1-AS drives progression in gastric cancer cells via miR-422a and BRD4, highlighting a potential therapeutic target.
Gastric cancer (GC) is a leading global cause of cancer-related mortality, necessitating urgent research on its pathogenesis, prevention, and treatment. In this study, we investigated the expressions of LncRNA BACE1-AS, mRNA BRD4, and miR-422a in GES-1 and GC cells under various treatments using RT-PCR. Western Blots confirmed protein expressions in HGC-27 and SNU-1 cells. EDU and MTT assays assessed cell proliferation, while Transwell tests determined invasion capacity, and flow cytometry analyzed apoptosis. BACE1-AS and BRD4 were significantly elevated in cancerous tissues compared to paired non-cancerous tissues. BACE1-AS knockdown inhibited invasion and proliferation, promoting apoptosis. miR-422a mimics suppressed proliferation and invasion while enhancing apoptosis, and miR-422a mimics with BRD4 overexpression had the opposite effect. Moreover, BAX protein increased in the si-BACE1-AS group but decreased in the si-BACE1-AS+miR-422a inhibitor group. Si-BACE1-AS and miR-422a mimics reduced the expression of C-Myc, CyclinD1, Survivin, CDK4, and Bcl-2, while the si-BACE1-AS+miR-422a inhibitor and miR-422a mimics+BRD4-OV groups showed the opposite trend. Our findings suggest that LncRNA BACE1-AS positively regulates gastric cancer progression by modulating BRD4 as a competitive endogenous RNA for miR-422a. This LncRNA BACE1-AS/BRD4/miR-422a signaling axis presents potential targets for developing therapeutic strategies against gastric cancer.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: